"Baker Bros. Advisors, led by billionaires Julian and Felix Baker, manages nearly $9.36 billion in biotech stocks, showcasing their influence in the sector."
"The firm made 41 moves in Q4 2024, but one notable change involved selling 80% of its holdings in a promising French biopharmaceutical firm."
Billionaires Julian and Felix Baker, with a net worth of $2.8 billion each, run Baker Bros. Advisors, a hedge fund that focuses on biotech stocks. Their recent 13F holdings report revealed $9.36 billion in assets across 95 securities. In Q4 2024, the firm made over 40 moves, including significant adjustments in prominent biotech investments. They notably sold 80% of their holdings in DBV Technologies despite its advanced clinical trial stage for an immunotherapy product, reflecting the volatile nature of biotechnology investments.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]